Three research collaboration agreements inked between A*STAR and Servier
- POSTED: 19 Sep 2013 13:04
This graph is an experimental feature that tracks number of views over time.
Three Research Collaboration Agreements (RCAs) were inked on Thursday between Servier, France's largest privately-owned pharmaceutical company, and A*STAR's Singapore Immunology Network (SIgN).
SINGAPORE: Three Research Collaboration Agreements (RCAs) were inked on Thursday between Servier, France's largest privately-owned pharmaceutical company, and A*STAR's Singapore Immunology Network (SIgN).
The projects aim to discover and develop drugs that harness the immune system to tackle diseases such as cancer and autoimmune disorders.
A*STAR said by developing innovative therapeutic strategies that can accurately modulate the body's own defence mechanism, they hope to develop immunotherapeutic drugs that are more targeted, and therefore less likely to cause side effects.
Acting executive director of SIgN, Associate Professor Laurent Rénia, said: "We are very pleased that Servier is expanding their collaboration with us. This is an excellent example of how private companies and public research institutions can work hand-in-hand to translate medical science breakthroughs into innovative medicines to meet healthcare needs.
"I am confident that the convergence of our strengths -- SIgN's strong expertise in translational human immunology, and Servier's in-depth knowledge in drug discovery and development -- will push the frontiers of immunotherapy for complex and difficult-to-treat diseases."
Jean-Philippe Seta, MD and CEO of Servier, said: "The expansion of this partnership is expressing our goal to collaborate closely with leading scientists worldwide, to discover and develop innovative medicines, particularly in the field of cancer.
"We believe that the high quality of the research done at SIgN is a unique opportunity to achieve this goal."